The notification states that there isn’t any threat to product high quality due to the labelling error
A category 4 defect notification has been issued for an osteoporosis medication (inventory picture) (Picture: Getty)
A defect notification has been issued for medication used to deal with a persistent situation that causes bones to grow to be fragile.
The Medicines and Healthcare merchandise Regulatory Company (MHRA) issued a category 4 defect notification for the osteoporosis medication Ponlimsi (denosumab) 60mg resolution for injection in a pre-filled syringe. The defect was issued attributable to a labelling error on the packaging.
We use your sign-up to supply content material in methods you have consented to and to enhance our understanding of you. This may occasionally embrace adverts from us and third events based mostly on our understanding. You’ll be able to unsubscribe at any time. Learn our Privateness Coverage
Osteoporosis is a persistent situation that causes bones to grow to be fragile, brittle and porous. It’s typically known as the “silent illness” since its signs typically goes unnoticed till what ought to be a minor damage leads to damaged bones.
The medication is commonly used to deal with girls who’ve been via the menopause and males who’ve an elevated threat of bone fracture, equivalent to these receiving remedy for prostate most cancers.
- Combat to make sure sufferers outdoors London not denied life-saving remedy
- Omeprazole customers face two main well being dangers with one mistake
The warning was issued after Teva UK Restricted reported that the cartons of three batches state “For utility to the pores and skin”. The product is definitely licensed for subcutaneous (or “underneath the pores and skin”) use.
Affected lot batch numbers are:
The product administration ought to be carried out by an individual who has been adequately educated in injection strategies. These batches, due to this fact, is not going to be repackaged.
Teva UK Restricted have mentioned that every one future deliveries might be provided with a duplicate of this notification. This can remind healthcare professionals and sufferers that the product is for subcutaneous use.
Ponlimsi (Denosumab) 60mg Resolution for Injection in Pre-filled Syringe (Picture: Gov.UK)
The notification states that there isn’t any threat to product high quality due to this labelling error.
Other than the label, no different errors have been recognized with the product or supply system. The affected batches are due to this fact not being recalled.
Healthcare professionals are suggested to reassure sufferers that the product is for injection as described within the data leaflet.
The leaflet comprises clear directions to be used.
Sufferers who expertise adversarial reactions or have any questions on their remedy ought to search medical consideration.
Any suspected adversarial reactions ought to be reported by way of the MHRA Yellow Card scheme.
Leave a Reply